Drugs /

valganciclovir

Back to Drugs List

Overview

NCI Definition [1]:
A synthetic prodrug of ganciclovir, a nucleoside analogue of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, viral DNA synthesis, and viral replication. (NCI04)

Clinical Trials

View Clinical Trials for valganciclovir

Valganciclovir has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating valganciclovir, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open).

EBV Positive and HHV8 Positive are the most frequent biomarker inclusion criteria for valganciclovir clinical trials.

Lymphoma, lymphoproliferative disorder, and multicentric angiofollicular lymphoid hyperplasia are the most common diseases being investigated in valganciclovir clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Valganciclovir
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating valganciclovir and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
valganciclovir [chemical/ingredient], ganciclovir l-valyl ester, valganciclovir, vgcv, l-valine, 2-((2-amino-1,6-dihydro-6-oxo-9h-purin-9-yl)methoxy)-3-hydroxypropyl ester, l-valine, ester with ganciclovir, valganciclovir (substance), valganciclovir, valganciclovir (product), valcyte, valganciclovir
NCIT ID [1]:
C2629
SNOMED ID [1]:
C-55BD6

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.